Trial Profile
A 3-Month, Phase 1, Open-label, Fixed-dose, first-in-human study to access the safety, tolerability and pharmacokinetics of Risperidone Subcutaneous Implants in patients with Schizophrenia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Feb 2018
Price :
$35
*
At a glance
- Drugs Risperidone (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Endo Pharmaceuticals
- 20 Feb 2018 New trial record
- 01 Jan 2018 Results assessing Pharmacokinetics and Safety of Risperidone Subcutaneous Implants in two phase 1 studies, published in the Clinical Pharmacology in Drug Development